JP2022507781A5 - - Google Patents
Info
- Publication number
- JP2022507781A5 JP2022507781A5 JP2021527836A JP2021527836A JP2022507781A5 JP 2022507781 A5 JP2022507781 A5 JP 2022507781A5 JP 2021527836 A JP2021527836 A JP 2021527836A JP 2021527836 A JP2021527836 A JP 2021527836A JP 2022507781 A5 JP2022507781 A5 JP 2022507781A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- alkyl
- amino acid
- compound according
- acid residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025106091A JP2025138724A (ja) | 2018-11-20 | 2025-06-24 | Lxrアゴニストとしての使用のためのビス-オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862769946P | 2018-11-20 | 2018-11-20 | |
| US62/769,946 | 2018-11-20 | ||
| PCT/US2019/062302 WO2020106780A1 (en) | 2018-11-20 | 2019-11-19 | Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as lxr agonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025106091A Division JP2025138724A (ja) | 2018-11-20 | 2025-06-24 | Lxrアゴニストとしての使用のためのビス-オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022507781A JP2022507781A (ja) | 2022-01-18 |
| JP2022507781A5 true JP2022507781A5 (cg-RX-API-DMAC7.html) | 2022-11-29 |
| JP7702866B2 JP7702866B2 (ja) | 2025-07-04 |
Family
ID=69005818
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021527836A Active JP7702866B2 (ja) | 2018-11-20 | 2019-11-19 | Lxrアゴニストとしての使用のためのビス-オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート |
| JP2025106091A Pending JP2025138724A (ja) | 2018-11-20 | 2025-06-24 | Lxrアゴニストとしての使用のためのビス-オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025106091A Pending JP2025138724A (ja) | 2018-11-20 | 2025-06-24 | Lxrアゴニストとしての使用のためのビス-オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート |
Country Status (20)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3042428A1 (en) | 2016-11-08 | 2018-05-17 | Regeneron Pharmaceuticals, Inc. | Steroids and protein-conjugates thereof |
| KR20250008984A (ko) | 2017-05-18 | 2025-01-16 | 리제너론 파마슈티칼스 인코포레이티드 | 사이클로덱스트린 단백질 약물 접합체 |
| WO2019217591A1 (en) | 2018-05-09 | 2019-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-msr1 antibodies and methods of use thereof |
| CA3120528A1 (en) * | 2018-11-20 | 2020-05-28 | Regeneron Pharmaceuticals, Inc. | Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as lxr agonists |
| US12605459B2 (en) * | 2020-07-13 | 2026-04-21 | Regeneron Pharmaceuticals, Inc. | Protein-drug conjugates comprising camptothecin analogs and methods of use thereof |
| MX2023004935A (es) | 2020-11-10 | 2023-07-07 | Regeneron Pharma | Conjugados de anticuerpos y selenio. |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| CA3224492A1 (en) | 2021-07-19 | 2023-01-26 | Xiaojun Han | Immunoconjugates and methods |
| CA3228214A1 (en) * | 2021-11-02 | 2023-05-11 | Changjiang Huang | Antibody-drug conjugate intermediate comprising sn38 and preparation method therefor |
| CN115594766A (zh) * | 2021-12-30 | 2023-01-13 | 辽宁键凯科技有限公司(Cn) | 一种缀合物及用其制备的抗体偶联药物 |
| CN115505028A (zh) * | 2022-09-16 | 2022-12-23 | 辽宁键凯科技有限公司 | 一种分支型聚乙二醇连接子及其用途 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| EP1239855A4 (en) | 1999-12-13 | 2004-04-21 | Merck & Co Inc | METHOD FOR PREVENTING AND TREATING ARTERIOSCLEROSIS |
| US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
| US6908934B2 (en) * | 2001-06-11 | 2005-06-21 | Merck & Co., Inc. | Therapeutic compounds for treating dyslipidemic conditions |
| EP1398032A1 (en) | 2002-09-10 | 2004-03-17 | PheneX Pharmaceuticals AG | 4-Oxo-quinazolines as LXR nuclear receptor binding compounds |
| TW200539855A (en) | 2004-03-15 | 2005-12-16 | Wyeth Corp | Calicheamicin conjugates |
| CA2570496A1 (en) | 2004-06-24 | 2006-01-05 | Galapagos N.V. | Methods and compositions to promote bone homeostasis |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| EP2121621B1 (en) | 2006-12-08 | 2014-05-07 | Exelixis Patent Company LLC | Lxr and fxr modulators |
| US8993628B2 (en) | 2007-02-23 | 2015-03-31 | City Of Hope | Synthetic ligands selective for LXRβ over LXRα, identification and methods of use thereof |
| WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
| US7985557B2 (en) | 2007-05-23 | 2011-07-26 | Ventana Medical Systems, Inc. | Polymeric carriers for immunohistochemistry and in situ hybridization |
| UA108598C2 (xx) | 2008-04-30 | 2015-05-25 | Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери) | |
| KR101000067B1 (ko) | 2008-12-30 | 2010-12-10 | 엘지전자 주식회사 | 고효율 태양전지용 레이저 소성장치 및 고효율 태양전지 제조방법 |
| PT2528625E (pt) | 2010-04-15 | 2013-10-17 | Spirogen Sarl | Pirrolobenzodiazepinas e conjugados das mesmas |
| US20130244905A1 (en) | 2010-07-06 | 2013-09-19 | Ed Grabczyk | Reporter for RNA Polymerase II Termination |
| DK2714685T3 (en) | 2011-05-27 | 2017-01-09 | Ambrx Inc | FORMATIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID BOUND dolastatin |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| AU2012322934B2 (en) | 2011-10-14 | 2016-09-08 | Medimmune Limited | Pyrrolobenzodiazepines |
| CA2850373C (en) | 2011-10-14 | 2019-07-16 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| JP6166728B2 (ja) | 2011-10-14 | 2017-07-19 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピンの製造に有用な合成方法及び中間体 |
| CA2850375C (en) | 2011-10-14 | 2019-07-02 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
| HRP20180268T4 (hr) | 2012-10-23 | 2026-03-27 | Synaffix B.V. | Modificirano antitijelo, konjugat antitijela i postupak za njihovu pripremu |
| BR112016014126B1 (pt) | 2013-12-16 | 2023-02-14 | Medimmune Limited | Composto não-peptídico, conjugados de anticorpo-fármaco do mesmo, uso dos ditos conjugados para o tratamento de câncer e composição farmacêutica que compreende os mesmos |
| SG11201605437YA (en) | 2014-01-27 | 2016-08-30 | Pfizer | Bifunctional cytotoxic agents |
| TWI871999B (zh) | 2014-04-10 | 2025-02-01 | 日商第一三共股份有限公司 | 抗her3抗體-藥物結合物 |
| US20160324981A1 (en) | 2015-05-08 | 2016-11-10 | The California Institute For Biomedical Research | Liver x receptor agonists and uses thereof |
| CA3001938A1 (en) * | 2015-11-04 | 2017-05-11 | Borealis Ag | A process for producing a multilayer laminate |
| EP3419670A2 (en) | 2016-02-26 | 2019-01-02 | Regeneron Pharmaceuticals, Inc. | Optimized transglutaminase site-specific antibody conjugation |
| CA3042428A1 (en) | 2016-11-08 | 2018-05-17 | Regeneron Pharmaceuticals, Inc. | Steroids and protein-conjugates thereof |
| EP3625209A1 (en) | 2017-05-18 | 2020-03-25 | Regeneron Pharmaceuticals, Inc. | Bis-octahydrophenanthrene carboxamides and protein conjugates thereof |
| WO2019217591A1 (en) | 2018-05-09 | 2019-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-msr1 antibodies and methods of use thereof |
| CA3120528A1 (en) * | 2018-11-20 | 2020-05-28 | Regeneron Pharmaceuticals, Inc. | Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as lxr agonists |
-
2019
- 2019-11-19 CA CA3120528A patent/CA3120528A1/en active Pending
- 2019-11-19 IL IL283313A patent/IL283313B2/en unknown
- 2019-11-19 EA EA202191430A patent/EA202191430A1/ru unknown
- 2019-11-19 EP EP19827877.2A patent/EP3883926B1/en active Active
- 2019-11-19 CN CN201980089547.4A patent/CN113382985A/zh active Pending
- 2019-11-19 US US17/295,420 patent/US12209180B2/en active Active
- 2019-11-19 SG SG11202105175WA patent/SG11202105175WA/en unknown
- 2019-11-19 MA MA53455A patent/MA53455B1/fr unknown
- 2019-11-19 ES ES19827877T patent/ES2984190T3/es active Active
- 2019-11-19 JP JP2021527836A patent/JP7702866B2/ja active Active
- 2019-11-19 AU AU2019384136A patent/AU2019384136B2/en active Active
- 2019-11-19 WO PCT/US2019/062302 patent/WO2020106780A1/en not_active Ceased
- 2019-11-19 MX MX2021005822A patent/MX2021005822A/es unknown
- 2019-11-19 MY MYPI2021002708A patent/MY206542A/en unknown
- 2019-11-19 KR KR1020217018084A patent/KR20210094568A/ko active Pending
- 2019-11-19 EP EP24186656.5A patent/EP4428142A3/en active Pending
- 2019-11-19 BR BR112021009673A patent/BR112021009673A2/pt unknown
-
2021
- 2021-05-19 CL CL2021001308A patent/CL2021001308A1/es unknown
- 2021-05-20 ZA ZA2021/03431A patent/ZA202103431B/en unknown
- 2021-05-20 PH PH12021551153A patent/PH12021551153A1/en unknown
- 2021-06-10 CO CONC2021/0007581A patent/CO2021007581A2/es unknown
-
2024
- 2024-12-16 US US18/983,183 patent/US20250171622A1/en active Pending
-
2025
- 2025-06-24 JP JP2025106091A patent/JP2025138724A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7754361B2 (ja) | 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩 | |
| JP7430643B2 (ja) | カンプトテシンペプチドコンジュゲート | |
| JP7843731B2 (ja) | ビス-オクタヒドロフェナントレンカルボキサミド及びそのタンパク質コンジュゲート | |
| AU2015273098B2 (en) | Auristatin derivatives and conjugates thereof | |
| KR20240095316A (ko) | Bcma 단일클론 항체 및 항체-약물 접합체 | |
| KR20210020015A (ko) | 항체에 대한 친화성 물질 및 생체 직교성 관능기를 갖는 화합물 또는 이의 염 | |
| JP2023535598A5 (cg-RX-API-DMAC7.html) | ||
| US20230405140A1 (en) | Anti-cd56 antibody-drug conjugates and their use in therapy | |
| ES2758506T3 (es) | Péptidos citotóxicos y conjugados de estos | |
| RU2586885C2 (ru) | Цитотоксические пептиды и их конъюгаты антитело-лекарственное средство | |
| JP2022542222A5 (cg-RX-API-DMAC7.html) | ||
| JP2017518304A5 (cg-RX-API-DMAC7.html) | ||
| JP2020520926A5 (cg-RX-API-DMAC7.html) | ||
| JP7702866B2 (ja) | Lxrアゴニストとしての使用のためのビス-オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート | |
| TWI838358B (zh) | 疏水性奧瑞他汀(auristatin)f化合物及其結合物 | |
| JP2017518359A (ja) | 親和性薬物コンジュゲート | |
| IL266202B2 (en) | Antibody-conjugated cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide γ receptors | |
| JP2013534528A (ja) | 脂質とコンジュゲートする抗体 | |
| JP2025510606A5 (cg-RX-API-DMAC7.html) | ||
| EP4536283A1 (en) | A method for programmatically managing antibody disulfide bonds site-specific modification | |
| KR20250117662A (ko) | 단백질 내재화를 위한 조성물 및 방법 | |
| JP2019507126A (ja) | ツブリシン類似体およびこれらの調製のための方法 | |
| JP2024542021A5 (cg-RX-API-DMAC7.html) | ||
| JP2024528719A (ja) | コンジュゲート化試薬及びそのコンジュゲート | |
| US20260027227A1 (en) | Novel thiol reductant, method and use thereof |